Fulvestrant (FUL) as first-line therapy in HR1ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

被引：0
|
作者：
Pronzato, P. [1 ]
Mustacchi, G. [2 ]
Riccardi, F. [3 ]
Turletti, A. [4 ]
Michelotti, A. [5 ]
Natoli, C. [6 ]
Livi, L. [7 ]
Del Mastro, L. [8 ]
Donadio, M. [9 ]
Garrone, O. [10 ]
Giordano, M. [11 ]
De laurentiis, M. [12 ]
Marchetti, P. [13 ]
Montemurro, F. [14 ]
Romagnoli, E. [15 ]
De Placido, S. [16 ]
Biganzoli, L. [17 ]
Cazzaniga, M. [18 ]
机构：
[1] ASST Monza, Genoa, Italy
[2] Univ Trieste, Trieste, Italy
[3] Azienda Osped Rilievo Nazl Antonio Cardarelli, UOSC Oncol, Naples, Italy
[4] Osped Martini ASLTO 1 Torino, Turin, Italy
[5] Osped S Chiara Pisa, UO Oncol Med 1, Pisa, Italy
[6] SS Annunziata Hosp, Oncol Unit, Chieti, Italy
[7] AOU Careggi, Radioterapia Oncol, Florence, Italy
[8] IRCCS SAN MARTINO IST Ist Nazl Ric Canc, SS Sviluppo Terapie Innovat, Genoa, Italy
[9] AOU Citta Salute & Sci, SSD Oncol Senol, Turin, Italy
[10] AOS Croce & Carle Osped Insegnamento, Oncol Med, Cuneo, Italy
[11] Osped St Anna Como, Oncol, Como, Italy
[12] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[13] Sapienza Univ Roma, Oncol Med, Rome, Italy
[14] Candiolo Canc Inst FPO IRCCS, Direzione Oncol Clin Invest, Turin, Italy
[15] Osped Macerata, UOC Oncol, Macerata, Italy
[16] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Oncol, Naples, Italy
[17] Osped Santo Stefano, USL Toscana Ctr, Oncol Med, Prato, Italy
[18] ASST Monza, Monza, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C25
引用
收藏
页数：1
相关论文
共 37 条
  • [1] First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study.
    Pronzato, Paolo
    Mustacchi, Giorgio
    Giordano, Monica
    Garrone, Ornella
    Del Mastro, Lucia
    Natoli, Clara
    Turletti, Anna
    Romagnoli, Emanuela
    Bologna, Alessandra
    Mocerino, Carmela
    Alu, Massimiliano
    De Angelis, Claudia
    Aversa, Caterina
    Arpino, Grazia
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Piezzo, Michela
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13-ambra study
    Cazzaniga, M. E.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Paolo, P.
    De Placido, S.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.
    Mustacchi, Giorgio
    Cazzaniga, Marina Elena
    Romagnoli, Emanuela
    Montemurro, Filippo
    De laurentiis, Michele
    Riccardi, Ferdinando
    Turletti, Anna
    Beano, Alessandra
    De Angelis, Claudia
    Graziano, Vincenzo
    Livi, Lorenzo
    Del Mastro, Lucia
    Biganzoli, Laura
    Garrone, Ornella
    De Placido, Sabina
    Marchetti, Paolo
    Pronzato, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly-Preliminary results of the GIM-13 AMBRA study.
    Mustacchi, Giorgio
    Pronzato, Paolo
    D'Alonzo, Alessia
    Mocerino, Carmela
    Romagnoli, Emanuela
    Garrone, Ornella
    Blasi, Livio
    De Laurentiis, Michelino
    Michelotti, Andrea
    Bologna, Alessandra
    Giordano, Monica
    Turletti, Anna
    Montemurro, Filippo
    De Placido, Sabino
    Natoli, Clara
    Taverniti, Cristiana
    Biganzoli, Laura
    Meattini, Icro
    Marchetti, Paolo
    Cazzaniga, Marina Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study
    Cazzaniga, Marina Elena
    De Placido, Sabino
    D'Alonzo, Alessia
    Piezzo, Michela
    Natoli, Clara
    Milani, Andrea
    Bologna, Alessandra
    Alu, Massimiliano
    Turletti, Anna
    Pugliese, Palma
    Biganzoli, Laura
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    Romagnoli, Emanuela
    Pronzato, Paolo
    Mustacchi, Giorgio
    CANCER RESEARCH, 2020, 80 (04)
  • [6] NAB-PACLITAXEL (NAB-P) IN HER2-VE ADVANCED BREAST CANCER (ABC) PATIENTS (PTS): FOCUS ON LUMINAL CANCERS. RESULTS FROM GIM13-AMBRA STUDY
    Cazzaniga, Marina Elena
    Mustacchi, Giorgio
    Bria, Emilio
    Bisagni, Giancarlo
    Biganzoli, Laura
    Pronzato, Paolo
    De Placido, Sabino
    Romagnoli, Emanuela
    Montemurro, Filippo
    Marchetti, Paolo
    De laurentis, Michelino
    Riccardi, Ferdinando
    Turletti, Anna
    Michelotti, Andrea
    Natoli, Clara
    Livi, Lorenzo
    Del Mastro, Lucia
    Donadio, Michela
    Garrone, Ornella
    Giordano, Monica
    BREAST, 2017, 36 : S51 - S52
  • [7] Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.
    Cazzaniga, Marina Elena
    Pronzato, Paolo
    Schettini, Francesco
    Del Mastro, Lucia
    Riemma, Maria
    Alu, Massimiliano
    Turletti, Anna
    Giordano, Monica
    Pugliese, Palma
    De Angelis, Claudia
    Garrone, Ornella
    Marchetti, Paolo
    Riccardi, Ferdinando
    Bernardo, Antonio
    Livi, Lorenzo
    Fabi, Alessandra
    Taverniti, Cristiana
    De Placido, Sabino
    Mustacchi, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13-AMBRA study
    Mustacchi, G.
    Cazzaniga, M.
    Bria, E.
    Bisagni, G.
    Biganzoli, L.
    Pronzato, P.
    De Placido, S.
    Romagnoli, E.
    Montemurro, F.
    Marchetti, P.
    De laurentiis, M.
    Riccardi, F.
    Turletti, A.
    Michelotti, A.
    Natoli, C.
    Livi, L.
    Del Mastro, L.
    Donadio, M.
    Garrone, O.
    Giordano, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] 2Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13-AMBRA study
    Mustacchi, G.
    Cazzaniga, M.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    Del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Riccardi, F.
    Marchetti, P.
    Montemurro, F.
    Romagnoli, E.
    De Placido, S.
    Biganzoli, L.
    Bisagni, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13-AMBRA Study
    Cazzaniga, M.
    Mustacchi, G.
    Giordano, M.
    Garrone, O.
    Donadio, M.
    del Mastro, L.
    Livi, L.
    Natoli, C.
    Michelotti, A.
    Turletti, A.
    Ferdinando, R.
    De laurentiis, M.
    Marchetti, P.
    Montemurro, M.
    Romagnoli, E.
    De Placido, S.
    Pronzato, P.
    Biganzoli, L.
    Bisagni, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2017, 28
1234